• Anlotinib Hydrochloride: Translating Multi-Kinase Inhibition

  2026-06-05

  Explore how Anlotinib hydrochloride, a leading multi-target tyrosine kinase inhibitor, enables next-generation, artifact-resistant angiogenesis and proliferation assays. This article uniquely connects pharmacokinetic depth, practical workflow optimization, and clinical context for advanced cancer research.

• Masitinib (AB1010): Technical Use in KIT/PDGFR Research

  2026-06-05

  Masitinib (AB1010) is a selective tyrosine kinase inhibitor for precise inhibition of KIT, PDGFRα, and PDGFRβ, enabling reliable modeling of KIT-driven signaling in cancer, mastocytosis, and inflammatory disease research. It is not suitable for workflows requiring broad-spectrum kinase inhibition or aqueous/ethanol-based systems, and should be handled following strict solubility and storage protocols.

• Live-Dead Cell Staining Kit: Precision Calcein-AM PI Assays

  2026-06-04

  The Live-Dead Cell Staining Kit enables robust, quantitative viability analysis in advanced experimental contexts, outperforming classic methods. Its dual-dye system supports high-content cytotoxicity, regenerative, and biomaterial research with flexible, protocol-driven workflows.

• Hexetidine (NSC-17764): Rethinking Antimicrobial Strategy in

  2026-06-04

  This article delivers a strategic, mechanistic, and translational roadmap for researchers leveraging Hexetidine (NSC-17764) as an antibacterial agent for oral infections and medical device-associated biofilms. By integrating experimental evidence, clinical context, and forward-looking guidance, the discussion equips translational scientists to address the enduring challenge of biofilm resistance and optimize protocols for real-world impact.

• Dovitinib (TKI-258): Decoding ERK-Driven Apoptosis in Cancer

  2026-06-03

  Explore how Dovitinib (TKI-258) enables precise dissection of ERK-mediated apoptosis and signal transduction in cancer models. This article offers a unique mechanistic focus, bridging advanced molecular insights with practical assay design.

• Macrophage EV miR-660 Drives Breast Cancer via KLHL21/NF-κB

  2026-06-03

  This study reveals how tumor-associated macrophage-derived extracellular vesicles (EVs) transfer microRNA-660 to breast cancer cells, downregulating KLHL21 and activating NF-κB signaling to promote metastasis. These results clarify a mechanistic link in the tumor microenvironment, supporting targeted strategies against cancer spread.

• Pravastatin Sodium: Optimized Workflows for HMG-CoA Reductas

  2026-06-02

  Leverage Pravastatin sodium for precise, reproducible HMG-CoA reductase inhibition in both cellular and animal models. This guide delivers actionable protocol enhancements, troubleshooting insights, and practical applications for cardiovascular and metabolic research—anchored by APExBIO’s trusted reagent quality.

• Ferrostatin-1 (Fer-1): Selective Ferroptosis Inhibitor in Di

  2026-06-02

  Ferrostatin-1 (Fer-1) is a potent, selective ferroptosis inhibitor with demonstrated nanomolar efficacy in preventing lipid peroxidation-driven cell death. Its robust activity underpins diverse experimental workflows in cancer biology, neurodegeneration, and atherosclerosis research. The compound's validated benchmarks and solubility profile make it a cornerstone for studying iron-dependent oxidative damage.

• Phosphatase Inhibitor Cocktail 2: Proteostasis, Aging, and A

  2026-06-01

  Explore how Phosphatase Inhibitor Cocktail 2 enables robust protein phosphorylation preservation in cutting-edge aging and neurodegeneration research. This article uncovers unique mechanistic and protocol-level insights for advanced signaling studies.

• HotStart™ 2X Green qPCR Master Mix: Protocol and Troubleshoo

  2026-06-01

  HotStart™ 2X Green qPCR Master Mix addresses nonspecific amplification and inconsistent quantification in SYBR Green–based real-time PCR workflows. It is best suited for gene expression analysis, RNA-seq validation, and nucleic acid quantification, but should not be substituted for probe-based qPCR or used where dye-based detection is unsuitable.

• Preclinical Characterization of Anlotinib: Selective VEGFR2

  2026-05-31

  This study presents a rigorous preclinical evaluation of anlotinib hydrochloride, a highly selective multi-target tyrosine kinase inhibitor with potent anti-angiogenic effects primarily via VEGFR2 inhibition. The findings highlight anlotinib's superior selectivity, in vitro and in vivo efficacy, and translational relevance for anti-angiogenic cancer research.

• Dual-Action Kinase Inhibitors Facilitate p38α MAPK Dephospho

  2026-05-30

  The referenced study uncovers that certain kinase inhibitors, including those structurally related to Imatinib hydrochloride, not only block kinase catalytic activity but also enhance dephosphorylation of p38α MAP kinase by stabilizing an activation loop conformation accessible to phosphatases. These findings provide a structural basis for dual-action inhibition and suggest new strategies for increasing specificity and potency in kinase inhibitor design for cancer research.

• Liposomal Co-Delivery of Cisplatin and Procainamide Hydrochl

  2026-05-29

  This study introduces a liposomal formulation co-encapsulating cisplatin and procainamide hydrochloride, demonstrating potentiated antiproliferative activity and reduced toxicity compared to cisplatin alone. The findings highlight the dual role of procainamide hydrochloride as both a cardiac sodium channel blocker and a modulator of chemotherapeutic response, suggesting new strategies for combinatorial drug delivery in oncology research.

• ABT-263 (Navitoclax) Workflows: Applied Apoptosis in Cancer

  2026-05-29

  ABT-263 (Navitoclax) is redefining apoptosis research in cancer biology, enabling precise, phase-specific cell death interrogation and translational workflow innovation. This article spotlights advanced experimental strategies, protocol best practices, and troubleshooting guidance for maximizing data quality with this potent Bcl-2 family inhibitor.

• Reliable Protein Labeling: NHS-Biotin (A8002) for Cell Assay

  2026-05-28

  This article delivers a scenario-driven, evidence-based overview of NHS-Biotin (SKU A8002) for researchers tackling challenges in cell viability, proliferation, and cytotoxicity assays. By anchoring each real-world Q&A in lab workflows, it showcases how NHS-Biotin’s chemistry, reproducibility, and vendor reliability translate into robust data and streamlined protocols for biomedical scientists.

15184 records 1/1013 page Next 12345 下5页 Last page